23andMe’s next challenge: ensuring its customers can get drugs developed with their data
23andme has long been known as a consumer genetic testing unicorn. But CEO Anne Wojcicki describes it differently, as “the people’s research company.”
The California-based unicorn is now focused on a partnership with pharma giant GlaxoSmithKline to discover new drugs using data culled from millions of 23andMe customers, and Wojcicki said Wednesday at the STAT Health Tech Summit that she hoped the company’s customers would “feel proud” if a drug developed with their data reaches the market.
